20 articles
24-week trial tested fucoxanthin-rich microalgae supplement on memory, attention, and executive function in 66 healthy seniors.
Probucol, a discontinued cholesterol medication, may boost brain-protective proteins in older adults at risk for dementia.
Cassava Sciences' 76-week Phase 3 trial of simufilam for Alzheimer's was terminated, raising questions about the drug's future.
A completed Phase 1/2 pilot trial tested whether the senolytic duo D+Q penetrates the brain in early Alzheimer's disease.
A Phase 2 trial investigates whether thiethylperazine, a decades-old antiemetic, can flush toxic amyloid beta from the brains of early AD patients.
18-month trial tested omega-3 supplementation in 774 older adults with low DHA/EPA levels and memory concerns to prevent cognitive decline.
Swiss researchers tested whether paroxetine reduces LSD response by downregulating serotonin receptors in healthy adults.
Italian researchers test plant-based compounds for brain health and quality of life in aging adults with promising early results.
Small trial tested whether fish oil and alpha lipoic acid could slow Alzheimer's by reducing oxidative stress markers in blood.
A VA-sponsored trial tested whether the blood pressure drug prazosin could remove toxic proteins linked to CTE and Alzheimer's in combat veterans.
A first-in-human multiple-ascending-dose trial tests Contraloid, an oral peptide designed to disassemble toxic amyloid-beta oligomers linked to Alzheimer's disease.
Contraloid acetate, an oral all-D-peptide designed to disassemble toxic amyloid-beta oligomers, completed its first-in-human safety trial in 40 healthy volunteers.
NGP 555 targets toxic brain protein production in healthy volunteers, offering potential early intervention for Alzheimer's prevention.
Italian researchers developed a biosensor to track extracellular vesicles in blood, potentially personalizing stroke rehabilitation.
A Phase 1/2 trial tests whether dexmedetomidine can enhance the brain's glymphatic system to clear amyloid and tau during sleep.
A completed pilot trial tests whether 2g/day of a novel carnosine formulation can restore neuromuscular function and quality of life in MS patients.
Phase 1b trial tests escalating doses of experimental Alzheimer's treatment BMS-984923 for safety and tolerability in older adults.
A completed Phase 4 trial from India evaluates whether ALA supplementation boosts flunarizine's migraine-prevention power in adolescents.
Small study tests psychedelic compound's safety and effectiveness against severe depression that doesn't respond to standard treatments.
A phase 2/3 trial of the BACE inhibitor atabecestat in amyloid-positive asymptomatic adults was terminated before completion, raising questions about this drug class.
